Tankyrases-1 and -2 (TNKS-1 and TNKS-2) have three cellular roles which make them important targets in cancer. Using NAD + as a substrate, they poly(ADP-ribosyl)ate TRF1 (regulating lengths of telomeres), NuMA (facilitating mitosis) and axin (in wnt/b-catenin signalling). Using molecular modelling and the structure of the weak inhibitor 5-aminoiso quinolin-1-one, 3-aryl-5-substituted-isoquinolin-1-ones were designed as inhibitors to explore the structure-activity relationships (SARs) for binding and to define the shape of a hydrophobic cavity in the active site. 5-Amino-3-arylisoquinolinones were synthesised by Suzuki-Miyaura coupling of arylboronic acids to 3-bromo-1-methoxy-5-nitro-isoquinoline, reduction and O-demethylation. 3-Aryl-5-methylisoquinolin-1-ones, 3-aryl-5-fluoroisoquinolin-1-ones and 3-aryl-5-methoxyisoquinolin-1-ones were accessed by deprotonation of 3-substituted-N,N,2-trimethylbenzamides and quench with an appropriate benzonitrile. SAR around the isoquinolinone core showed that aryl was required at the 3-position, optimally with a para-substituent. Small meta-substituents were tolerated but groups in the ortho-positions reduced or abolished activity. This was not due to lack of coplanarity of the rings, as shown by the potency of 4,5-dimethyl-3-phenylisoquinolin-1-one. Methyl and methoxy were optimal at the 5-position. SAR was rationalised by modelling and by crystal structures of examples with TNKS-2. The 3-aryl unit was located in a large hydrophobic cavity and the parasubstituents projected into a tunnel leading to the exterior. Potency against TNKS-1 paralleled potency against TNKS-2. Most inhibitors were highly selective for TNKSs over PARP-1 and PARP-2. A range of highly potent and selective inhibitors is now available for cellular studies.
Introduction
Tankyrase-1 (PARP-5a, TNKS-1, ARTD5) and tankyrase-2 (PARP5b, TNKS-2, ARTD6) are members of the poly(ADP-ribose)polymerase (PARP) superfamily of enzymes, which attract considerable current interest owing to their roles at telomeres and involvement at the mitotic spindle and in the wnt signalling pathway. TNKS-1 was first reported in 1998, 1 as regulating the lengths of telomeres through poly(ADP-ribosyl)ation of telomere repeat binding factor-1 (TRF-1) and autopoly(ADP-ribosyl)ation. 2, 3 NAD + is the source of the ADP-ribose (ADPr) units, as for other PARPs. 4 TNKS-1 is also responsible for poly(ADP-ribosyl)ating NuMA at the mitotic spindle, ensuring its correct functioning during mitosis. 5 Furthermore, TNKS-1 is a component of the wnt signalling system, where it poly(ADP-ribosyl)ates axin. Poly(ADPr)-axin is thus tagged for ubiquitinylation and destruction through the proteasome, increasing the levels of b-catenin, while decreasing the levels of phosphorylated b-catenin. 6, 7 Accumulation of b-catenin leads to a proliferative signal in the nucleus. 7 The closely structurally related isoform TNKS-2 can substitute for TNKS-1 in many, but not all, of these activities. 2, 8, 9 Telomeres are protected by the shelterin complex of six telomere-specific proteins. Its main role is to protect the telomere from being recognised as a site of damage by the DNA-repair machinery, http://dx.doi.org/10.1016/j.bmc.2015.06.061 0968-0896/Ó 2015 Elsevier Ltd. All rights reserved.
TNKSs in mitosis is in resolution of the telomeres. 13, 18, 19 TNKSs are over-expressed in several clinical cancers and cancer cell lines, including breast cancer, 20, 21 colon cancer, 22, 23 chronic myeloid leukaemia, 24 brain tumours, 25, 26 and gastric 27 and bladder cancers, 28 pointing to one or more critical roles. Seimiya 29 proposed them as therapeutic targets on the basis of their roles at telomeres. Subsequent revelation of the roles of TNKSs in wnt signalling 7 and the observation of aberrant wnt signalling in many tumour types 30 has reinforced their value as targets for anti-cancer drug design. 31, 32 One TNKS inhibitor has shown activity in an APCmutant mouse model of colon cancer. 33 The role of TNKS-1 in the replication of Herpes simplex virus may also point to applications in the treatment of viral infections. 34 These observations and opportunities point to the need for potent and selective inhibitors of the TNKSs and for a greater understanding of the detail of the binding pockets around the NAD + -binding site. Figure 1 shows the structures of some known inhibitors of the TNKSs. XAV939 1 7 and GM244-LM 2 35 both bind at the nicotinamide-binding site, as do our 2-arylquinazolin-4-ones 3 36, 37 and flavones, including 4. 38, 39 Our lead water-soluble inhibitor of PARP-1 and PARP-2, 5-AIQ 11a, [40] [41] [42] [43] [44] binds only weakly to the TNKSs, with IC 50 in the low lM range (preliminary data not shown). Compound 5 binds with its quinazolin-4-one at the nicotinamide-binding site and the side-chain extending to make interactions in the adenosine-binding site of the NAD + -binding cleft. 45 EB-47 6 occupies both the nicotinamide-and adenosinebinding pockets but with a linker that uses a different path on the enzyme surface. 46 Compound 7 uses an amino-1,2,4-triazole to make the requisite H-bonds within the nicotinamide-binding site, 47 whereas 8 uses a dihydropyranopyrimidine to bind there. 48 
IWR1
9 49 and G007-LK 10 35, 50 bind to the adenine-binding site alone.
We present here our structure-based design of 3-arylisoquinolin-1-ones as inhibitors of the TNKSs and our exploration of the structure-activity relationships (SARs) around this core and binding, guided by crystallography and studies in silico. Using rational modification of the substituents around the core, the aim of this study is to explore the detail of the conformational and space-filling requirements for optimum occupation of a large hydrophobic cavity in the enzymes adjacent to the nicotinamide-binding site.
Results and discussion

Design of inhibitors
The design of the isoquinolin-1-one inhibitors was approached from three start-points. Firstly, we solved the crystal structures of our water-soluble PARP-1 inhibitors 11a, 40 11b, 51 11c, 51 and 11d
52
( Fig. 1 ) bound into the NAD + -binding site of the catalytic domain of human TNKS-2. These compounds were shown, in preliminary studies, to be weak inhibitors of the TNKSs (IC 50 >10 lM) (data not shown). Secondly, the structure of XAV939 1 bound into the catalytic domain of TNKS-2 is available. 53 Thirdly, we sought to investigate 'scaffold-hopping' from our 2-arylquinazolin-4-one inhibitors, from our preliminary studies, 36 to the 3-arylisoquinolin-1-ones. 11a-d was accommodated in a small pocket and there was a small niche to accept the 4-methyl in 11d. There is a large cavity adjacent to the 3-position of the isoquinolin-1-ones; the small 3-alkyl groups of 11b,c were located in this cavity near to the entrance. The cavity is lined with aromatic and hydrophobic residues (mainly Pro , with a small tunnel leading from the far end of the hydrophobic cavity towards the exterior. The size and shape of the hydrophobic cavity suggest that it could accommodate a benzene ring, with modest substituents. A water molecule was evident in the centre in complexes of the 3-H isoquinolinones 11a,d, whereas two water molecules were seen towards the sides of the cavity when it was partly occupied by ethyl in 11b. The pentyl group in 11c was too large to allow an ordered water molecule in the cavity. Figure 2C shows a cartoon of the arrangement of the hydrophobic cavity and the tunnel, relative to the H-bonding motif anchoring the lactam of 11a. 34 This fits well with our predictions from our results on the binding of 11a-d with TNKS-2, in that the phenyl ring of 1 occupies much of the hydrophobic cavity and the trifluoromethyl group is located at the entrance to the tunnel. The SAR from our preliminary study 36 on the 2-arylquinazolin-4-ones suggested that the lactam H-bonding motif was essential and that a para-substituted benzene ring could be accepted by the hydrophobic cavity. One example, (3: R 4 0 = CH 2 NHCbz, R 8 = Me) projected deep into the tunnel, with only slight loss of activity. The preliminary SAR also suggested the need for a small substituent at the 8-position (R 8 in 3, Fig. 1 , corresponding to the 5-position in isoquinolin-1-ones (R 5 in 11)). This SAR was rationalised by modelling studies. The structures of the designed isoquinolin-1-ones 12-17 are shown in Figure 3 . All contain the 3-arylisoquinolin-1-one core, as predicted by the structural studies and comparison with the 2-arylquinazolin-4-ones to be required. All carry a 5-substituent, as this was better in the quinazolin-4-ones. 36 However, the nature of the 5-substituent was not clearly predicted and comparison of compounds in the series 12-16 may clarify this. Compounds 12 and 16 have H-bond-donor electron-donating groups (EDGs) (the 5-NH 2 in 12 is unprotonated at physiological pH), whereas 15 contain a H-bond-acceptor EDG. Analogues 13 and 14 have nonpolar 5-substituents, which is electron-neutral in 13 and electron-withdrawing in 14. Within each series, especially 12 and 13, the nature, size and location of the substituent on the 3-aryl group is explored. Substituents range from polar H-bond-donors (in 12p,t,u), through H-bond-acceptors (in 12d-f, 13d, 14c, 15h) to non-polar groups and atoms (in 12b,c,g-n, 13b,c,e-j, 14b,d-g, 15b-f, 16b). Strongly electron-donating, electron-neutral and electron-withdrawing substituents were investigated. Unsubstituted 3-phenyl was examined in 12a, 13a, 14a, 15a, 16a. Weakly basic and neutral heterocycles (replacing the 3-phenyl) were incorporated in 13p-r, 14h, 15g-i, some being electron-poor and some being electron-rich. The optimal location of the substituent on the 3-aryl ring was tested in five sets of compounds, 12b,c, 12d-f, 12g-i, 12k-n and 13f-h. The effect of an ortho-substituent may be to twist the 3-aryl ring out of the plane of the isoquinolinone; this potential twist was replicated in 17 with a methyl group in the 4-position ('ortho' to the phenyl).
The preliminary SAR in the quinazolin-4-one series 36 and the crystal structures used here gave limited predictive information on the precise dimensions and the flexibility of the hydrophobic cavity; thus we tested these with the greater steric bulk of 12n, 13c,i,q, 15h and, in extremis, by the ferrocene in 13s. The dimensions were also tested by inserting a CH 2 CH 2 spacer between the isoquinolinone and the phenyl ring in 12s. The tunnel at the end of the hydrophobic cavity distal from the isoquinolinone-binding subsite would be occupied by a long rigid hydrophobic group in 13k. This space was also explored in 13l-o. The latter compounds incorporate a tertiary aliphatic amine to aid water-solubility; a protonated primary aliphatic amine in this position leads to major loss of activity in the quinazolin-4-ones 36 and an aniline may not be sufficiently basic for formation of soluble salts.
Chemical synthesis
5-AIQ 11a (Fig. 1 ), has been prepared by a number of different routes, including Polonovski rearrangement of 5-nitroisoquinoline-N-oxide followed by reduction of the nitro group 56 and selective reduction of the nitrile of methyl 2-cyanomethyl-3-nitrobenzoate, 57 cyclisation in situ and further reduction. The current optimum method is condensation of methyl 2-methyl-3-nitrobenzoate with DMFDMA, hydrolysis of the enamine to 5-nitroisocoumarin, conversion to 5-nitroisoquinolin-1-one and reduction. 40 However, none of these routes can be adapted readily to the preparation of a library of 3-substituted analogues. We previously reported some approaches to the target compounds (Scheme 1) but each suffers from lack of generality and modest yield and none feature late introduction of the 3-substituent, a requirement for efficient preparation of a focussed library. Sonogashira coupling of methyl 2-iodo-3-nitrobenzoate 18 with phenylethyne, followed by 6-endo-dig cyclisation of the alkyne 19, gave the isocoumarin 20 (R 3 = Ph), 58 leading to 22 (R 3 = Ph) and hence to 12a (R 3 = Ph). Similar electrophilic cyclisation of 19
with ICl led to the isocoumarin 21 and hence to 20 (R 3 = Ph). 58 The initial Sonogashira reaction was limited to this example. Reaction of 23 with Cu(I) phenylacetylides under CastroStephens conditions gave the 17 directly but only when R 3 = Ph, 4-MePh and 4-MeOPh. 58 Hurtley couplings of the corresponding bromonitrobenzoic acid 24 afforded a wide range of intermediate isocoumarins 20 directly but the yields were modest and the reaction was limited to R 3 = alkyl, electron-rich aryl. 51 Nevertheless, samples of 12a,c,f,m were prepared for this study. Finally, treatment of 25 with benzoyl chlorides under Friedel-Crafts conditions gave modest yields of 20 but this process failed for electron-donating substituents. 59 There was, therefore, a pressing need to design a synthetic route which allowed efficient late incorporation of diverse 3-substituents.
We have previously described Pd-catalysed Suzuki-Miyaura and Stille couplings to 1-alkoxy-4-bromo-5-nitroisoquinolines as a method to access 4-substituted analogues of 5-AIQ 11a, which are inhibitors of PARP-2. 60 Adaptations of this method were explored to access the required corresponding 3-aryl-5-AIQs. 1,3-Dichloroisoquinoline 26 was nitrated selectively at the 5-position under highly acidic conditions to give 27 (Scheme 2).
A methoxy group at the 1-position would serve as a masked lactam; the lactam in the target compounds is essential for biological activity but it also renders the isoquinolin-1-ones highly insoluble in organic solvents used for coupling reactions. This methoxy group was introduced using methoxide ion in methanol, giving 28; this reaction is highly selective for displacement of the chlorine at the 1-position, with no reaction at the 3-position even under prolonged or more forcing conditions. Pd-catalysed coupling of an appropriate 3-chloroisoquinolin-1-one would be desirable, as it places the point of introduction of diversity very late in the sequence, such that each coupled analogue only required one further step to generate the targets 12. Demethylation of 28 with hydrogen bromide in acetic acid gave 29 in moderate yield (Scheme 2). However, this material was very poorly soluble in solvents appropriate for Suzuki-Miyaura couplings and all attempts to couple it with arylboronic acids failed.
By contrast, 28 (containing the lactam masked as the 1-methoxy group) had excellent solubility in common organic solvents. Coupling with arylboronic acids carrying simple substituents at ortho-, meta-or para-positions, using a Pd 2 dba 3 /SPhos combination in boiling toluene was moderately effective, giving 12a,d,e,gi,k,l,p-r in moderate yields. Varying amounts of unreacted 28 were recovered but the unreacted boronic acids decomposed under the reaction conditions. Repetition of the reactions with excess arylboronic acids, either from the start of the reaction or added portionwise during the procedure, failed to increase the yields. The yields of isolated 3-arylisoquinolines 30a,d,e,g-i,k,l,p-r were also lowered by difficulties in separation of 30a,d,e,g-i,k,l,p-r from 28. Catalytic hydrogenation reduced the nitro groups of 30a,d,e,g-i,k,l,p-r to the required amines in 31a,d,e,g-i,k,l,p-r. Palladium on charcoal was a satisfactory catalyst for most of the reductions but the monochlorophenylisoquinolines 30k,l also suffered reductive loss of the chlorine under these conditions (giving 31a). This dehalogenation was suppressed by the use of platinum on charcoal as catalyst. Curiously, 30n was not dehalogenated during formation of 31n.
It was rationalised that increasing the reactivity of the 3-haloisoquinoline would have two benefits: (a) the intrinsic yield would be higher, (b) separation of starting isoquinoline from product isoquinolines would be easier, as less of the former would be present in the product mixture before chromatography. 1,3-Dibromoisoquinoline 34 is not commercially available at an economical price and had to be synthesised in two steps from inexpensive homophthalic acid 32 (Scheme 3). Heating 32 with urea at 180°C in a solvent-free reaction gave the imide 33. An attempt to replace both oxygens with bromines using phosphorus tribromide gave a modest yield of 34, along with some of the deoxygenated side-product 35. Clearly, the P(III) reagent is responsible for this side-reaction and analogous treatment with phosphorus oxybromide, gave only 34. Nitration of 34 under highly acidic conditions afforded 36 in almost quantitative yield. As in the chloro series above, the 1-bromine could be replaced selectively with methoxide to give 37, with no evidence of reaction at the 3-position despite the increased leaving-group ability of Br versus Cl. The regioisomeric identity of 37 was confirmed by a HMBC NMR experiment, with correlation between the OCH 3 protons and isoquinoline 1-C and by NOE correlation between OCH 3 and 8-H. The increased reactivity of the 3-bromoisoquinoline 37 led to more effective SuzukiMiyaura couplings with a wide range of arylboronic acids to give 30. As shown in Scheme 3, this coupling tolerated a variety of substituents on the boronic acid. Steric bulk generally lowered the yield but the 2,6-dichloro analogue 30n was formed from 37. Changing the reaction solvent to DMF and raising the reaction temperature to 135°C raised the yields. Table 1 shows direct comparisons between the yields obtained in coupling using the 3-chloroisoquinoline 28 and the 3-bromoisoquinoline 37 as the haloarene component. In general, yields were improved with 37 and with DMF as reaction solvent. The highly reactive 37 also permitted coupling with 4-bromophenylboronic acid, without homo-coupling of the boronic acid. The poor solubility of 4-hydroxyphenylboronic acid in toluene led to very low yields for couplings in this solvent but DMF enabled preparation of 30p in good yield from 28 and from 37.
There are two possible sequences from 30 to the targets 12, demethylation then reduction or vice versa. The former was investigated with three examples. Demethylation of 30a,i,j with hydrogen bromide in acetic acid gave the corresponding 3-aryl-5-nitroisoquinolin-1-ones 22a,i,j in good yields. However, the poor solubility of these nitroisoquinolin-1-ones in solvents appropriate for catalytic hydrogenation of the nitro groups precluded efficient conversion to 22a,i,j. Thus 30g-n,p-r were first reduced to 31g-n,p-r, using hydrogen and Pd or Pt as appropriate (Pt was required for some examples to avoid reductive dehalogenation). Demethylation was effected with hydrogen bromide in 
acetic acid, a medium in which the 5-aminoisoquinolines were readily soluble, to furnish the required 12g-n,p-r in good yields as their HBr salts. There was no evidence of demethylation of the 4 0 -methoxy group in 31f, indicating the selectivity of the conditions chosen. The nitriles in 31q,r were hydrated under these vigorous conditions to give the carboxamides 12t,u, rather than 12q,r.
Sonogashira coupling of phenylethyne to the 3-bromoisoquinoline 37 was also high yielding, giving the 3-phenylethynyl analogue 38. The nitro group of 38 could not be reduced selectively but catalytic hydrogenation provided 39. Demethylation afforded 12s as the hydrobromide salt.
The 5-methyl-, 5-fluoro-, 5-methoxy-and 5-hydroxy-3-arylisoquinolin-1-ones 13a-s, 14a-h, 15a-i and 16a,b were prepared by a different route (Scheme 4). Poindexter described a route to simple 3-arylisoquinolin-1-ones by double deprotonation of N,2-dimethylbenzamide with butyllithium and reaction with benzonitriles. 61 Cho et al. extended this method to removal of a proton from the Ar-CH 3 of the tertiary amide N,N,2-trimethylbenzamide with lithium diisopropylamide at À78°C and subsequent reaction with benzonitriles lacking acidic functional groups. 62 We have extended this process to the synthesis of 3-aryl-5-substitutedisoquinolin-1-ones from N,N,2,3-tetramethylbenzamide 41, 3-fluoro-N,N,2-trimethylbenzamide 49 and 3-methoxy-N,N,2-trimethylbenzamide 51. The advantage of this route is that the diversity in the 3-aryl substituent is introduced at the final stage of the synthesis, through diversity in the benzonitriles.
2,3-Dimethylbenzoic acid 40 was converted into its N,Ndimethylamide 41 in the usual way. Treatment with one equivalent of LDA in THF at À78°C selectively removed a proton from the 2-CH 3 . The anion reacted with a range of benzonitriles to provide the corresponding 3-aryl-5-methylisoquinolin-1-ones 13a-j in poor-to-excellent yields. The lower yields were due not to failure of reaction but to issues in isolation of these compounds which are of limited solubility in convenient organic solvents; sufficient material was obtained in each case for biochemical evaluation. The reaction was sensitive to steric crowding in the benzonitrile, with 2-chlorobenzonitrile and 2,6-dichlorobenzonitrile giving low yields of 13f,i, respectively. No transmetalation was seen with 4-bromobenzonitrile, which gave a satisfactory yield of 13j. The reaction was also applicable to heterocyclic nitriles, with 4-cyanopyridine, 5-cyanobenzo-1,3-dioxole and 3-cyanothiophene reacting well with the anion derived from 41 to give the 3-heteroaryl-5-methylisoquinolin-1-ones 13p-r.
Isoquinolin-1-ones 13k-o carry extensions at the 4 0 -position of the 3-phenyl substituent either to probe the far side of the hydrophobic pocket or to elicit solubility in water but the corresponding benzonitriles 43,45a-d are not commercially available. Sonogashira coupling of 4-bromobenzonitrile 42 with phenylethyne gave 4-phenylethynylbenzonitrile 43 in good yield. The 4-(aminomethyl)benzonitriles 45a-d were prepared from 4-bromomethylbenzonitrile 44 and secondary amines, under a variety of basic conditions (Scheme 4). These benzonitriles gave the corresponding isoquinolinones 13k-o. These analogues 13l-o were converted to their hydrochloride salts, which showed much-enhanced aqueous solubility. The 3-ferrocenylisoquinolinone target 13s tests whether the hydrophobic pocket could accommodate three-dimensional steric bulk while still retaining aromaticity, rather than the planar aromatic 3-substituents of 13a-r. Commercially available ferrocenecarboxylic acid 46 was converted into its carboxamide, which was dehydrated into the nitrile 47 in high yield. Reaction with the anion of 41 proceeded in moderate yield to give 10s, despite the steric bulk of the ferrocene.
This one-step assembly of 3-aryl-5-substituted isoquinolin-1-ones was extended into the 5-fluoro analogues 14a-h and the 5-methoxy compounds 15a-i (Scheme 4). 3-Fluoro-3-methylbenzoic acid 48 and 3-methoxy-2-methylbenzoic acid 50 were readily converted into the corresponding N,N-dimethylbenzamides 49, 51, respectively, via the acid chlorides. Again, the derived anions reacted smoothly with a range of benzonitriles to give 14a-h and 15a-i, confirming that neither the deprotonation of the Ar-CH 3 nor the subsequent attack of the carbanion on the nitrile and cyclisation were adversely affected by the electron-withdrawing fluorine or the electron-donating methoxy group ortho to the methyl. Two examples 15a,d were demethylated at the 5-position to provide the corresponding 5-hydroxyisoquinolin-1-one 16a,b using boron tribromide. 4-Alkylisoquinolin-1-ones have been prepared by Stille coupling of 4-bromo-1-methoxyisoquinolines 60 and by Pd-catalysed double-bond migration and cyclisation of N-allyl-2-halobenzamides. 52 However, neither of these methods provides a short access to 4,5-dimethyl-3-phenylisoquinolin-1-one 17. This target was approached by twice exploiting the nucleophilic reactivity of the CH 2 -carbanion ortho to the lithium-coordinating dimethylamide. N,N,2,3-Tetramethylbenzamide 41 was deprotonated selectively at the 2-CH 3 and reaction with iodomethane gave the 2-ethyl analogue 52. However, treatment of 52 with lithium diisopropylamide failed to give the corresponding ArC (À) HMe anion, as shown by the lack of incorporation of deuterium upon quench with deuterium oxide. The stronger base, sec-butyllithium, was successful in removing one of the methylene protons and reaction of the anion with benzonitrile gave 17, demonstrating that this synthesis of isoquinolin-1-ones is applicable to 4-alkyl analogues.
Biochemical evaluation
Target compounds were initially screened for inhibition of the activity of TNKS-2 at 1.0 lM, 100 nM and 10 nM using immobilised truncated human TNKS-2 containing the catalytic (NAD ; the biotinylated poly(ADP-ribose) is then quantified with streptavidin-horseradish peroxidase. 36 The data are shown in Table 2 . IC 50 values were then determined for examples selected for potency at 10 nM and which would give detailed information about the structural requirements for activity (Table 2 ). Many selected compounds were also evaluated for inhibition of full-length human TNKS-1 (using immobilised histones as co-substrate) and counter-screened against human PARP-1 36 and murine or human PARP-2 to assess selectivity ( Table 2 ). The PARP-1 assays were conducted using a commercial kit; PARP-2 assays were conducted for 11a, 12a,f,i,m with murine PARP-2 as described previously 63 and for 13b,k,p, 14b, 15b with human PARP-2 using a commercial kit.
2.4. Structure-activity relationships 2.4.1. Structure-activity relationships-5-position Examining the data for inhibition of TNKS-2 (Table 2 ), a trend is evident for the 5-substituent. Comparing the six analogues 12i, 13e, 14d, 15d, 16b, 22i where the 3-substituent is kept constant as 4-trifluoromethylphenyl, potency increases in the order 5-F < 5-NO 2 = 5-OH < 5-NH 2 < 5-Me = OMe. This trend is also observed for the entire set of 3-arylisoquinolinones. The data suggest that an electron-donating or electron-neutral hydrophobic group is optimum at this 5-position, with the electron-withdrawing fluorine and nitro groups having diminished activity. Similarly, H-bond donors (hydroxy, amino) reduce the inhibitory potency and hydrophobic groups (methyl, methoxy) are preferred. Finally, modest size improves activity, with the 5-fluoro compounds showing lower potency; C-F occupies similar steric space as does C-H. Interestingly, this correlates with the observed preference for 8-methyl and 8-methoxy in the 2-arylquinazolin-4-one series (corresponding to the 5-position in isoquinolinones), where the 5-H compound was significantly less active. 36 This trend can be rationalised structurally by considering that the space available to this 5-substituent is expected to be that occupied by the ribose anomeric carbon and adjacent 2 0 -CHOH and ether oxygen when NAD + is bound. 
Structure-activity relationships-exploration of the hydrophobic cavity
Comparison of 11a with the 3-phenyl analogue 12a shows the need for a 3-aryl group. The nature and substitution of this group have a major role in determining potency, according to whether or not the substituted aryl can be accommodated in the hydrophobic cavity. The 3-(unsubstituted-phenyl)isoquinolinones 12a, 13a, 14a, 15a, 16a all have good potency, taking into account the effect of the nature of the 5-substituent. The location of the groups attached to the 3-phenyl is seen to have a profound effect on binding. Within the isomeric set of 5-amino-3-(methoxyphenyl) isoquinolin-1-ones 12d-f, the methoxy substituent appears to be moderately well tolerated at the meta-and para-positions of the 3-phenyl (in 12e,f) but not at the ortho-position, leading to inactivity of 12d below micromolar concentrations. A similar strong trend is seen for the corresponding isomeric set of 5-amino-3-(chlorophenyl)isoquinolin-1-ones 12k-m but the para-chlorophenyl compound 12m also appears to be marginally more active than the meta-analogue 12l. Compound 12n, with chlorines in both ortho-positions, is completely inactive. The same trend is also strongly evident in moving to the 5-methyl series, in that the para-chloro compound 13h is very potent, the meta-chloro isomer 13g is marginally less potent, with even lower activity for the ortho-chloro isomer 13f. Again, the 2 0 ,6 0 -dichloro analogue 13i completely lacks activity. Thus the trend for optimum location of substituents on the 3-phenyl ring appears to be 4 0 > 3 0 ) 2 0 >>> 2 0 ,6 0 . We also observed this preference for flavones. 39 Interestingly, the benzo-1,3-dioxoles 13q and 15h retain activity; these can be considered as having the 3-phenyl rings disubstituted at the meta-and para-positions. There are two possible structural rationalisations for this trend. Firstly, the hydrophobic cavity may simply be limited in size and flexibility at the end nearer the isoquinolinone-binding motif and thus not be able to accommodate bulky ortho-substituents. In this rationalisation, the hydrophobic cavity is larger and/or more flexible at the distal end, near the tunnel to the exterior, to accommodate substituents in the meta-and para-positions. In an alternative rationalisation, it may be the dihedral (twist) angle between the phenyl and the isoquinoline rings that controls binding in the hydrophobic cavity. The phenyl-isoquinoline system is essentially a biphenyl-like structure and the two rings may twist dihedrally about the linking bond to avoid steric clashes between 2-H and 4-H on the isoquinoline and 2
0 -H and 6 0 -H on the phenyl. Of course, if any of these positions were occupied by a bulky substituent, the propensity to twist out of the mutual plane would be greater. In this rationalisation, the hydrophobic cavity may be oval in crosssection and rigid, allowing the phenyl ring to bind in one plane but not in others. Resolution of this dichotomy is achieved by inducing the dihedral twist between the rings without the orthosubstituents on the phenyl; 17 has a methyl at the 4-position on the isoquinoline, which should induce the twist to avoid steric clash with 2 0 -H and 6 0 -H on the phenyl. Small-molecule crystal structures were determined for 13i (carrying a 2 0 ,6 0 -dichlorophenyl) and for 15b, which carries only a para-methylphenyl (Fig. 4) . In 13i, the two chlorines force a twist of 67°between the rings, whereas the rings are almost coplanar in 15b, with a dihedral angle of only 1°. Unfortunately, the strict analogue 13h did not form crystals of sufficient quality for X-ray diffraction. Molecular modelling of 13h and 13i bound into the nicotinamide-binding pocket and the hydrophobic cavity of TNKS-2 showed dihedral angles between the rings for 13h (5°) and for 13i (60°) in minimised structures (Fig. 5) . The dihedral angles correlate with potency against the activity of the enzyme. Compound 17, in which dihedral twist between the rings should be induced by the 4-Me, did not form crystals of suitable quality for small-molecule X-ray structure determination. However, when soaked into the crystal of TNKS-2, it bound well and a crystal structure was determined (Fig. 6) . Similarly, a crystal structure was obtained for 15e bound into TNKS-2 (Fig. 6) . These crystal structures show that the rings are effectively coplanar in 15e, whereas the aromatic rings are significantly twisted relative to each other in 17. Thus the inhibitory activity towards TNKS-2 does not correlate well with the dihedral twist angle between the phenyl and isoquinoline rings, as 17 is only nine-fold less potent than 13a. Loss of inhibitory activity does, however, correlate with the presence of bulky ortho-substituents on the phenyl ring. Compounds 12d,k, 13f with only one ortho-substituent on the 3-phenyl retain limited activity at 1.0 lM, whereas those with both ortho-positions occupied by bulky substituents (12n, 13i) are completely inactive. This effect can be rationalised by considering 12d,k, 10f as existing as pairs of interconverting enantiomeric atropisomers, only one of which will bind to the enzyme, with the single ortho-substituent orientated away from steric clash with the protein. If there are two ortho-substituents, this is not possible and the compound cannot bind.
It can be seen that the optimum location for a substituent is the 4 0 -position, where it can interact with residues lining the hydrophobic cavity and/or project into the narrow tunnel. Accordingly, the size and nature of the 4 0 -substituent was studied. Across all series, several trends are evident. Particularly in 12 and 13, the 4 0 -unsubstituted compound is slightly less active, so a substituent is preferred. Small lipophilic and polar substituents are tolerated equally, the former illustrated by 12c,i, 13b,d,e,h, 14b-d,f, 15b,d,e and the latter by 12p,u. Interestingly this was not observed for 5-unsubstituted 3-arylisoquinolin-1-ones, implying differences between the scaffolds. 37 The electronic characteristics of the 4 0 -substituent also appear to be unimportant, comparing electron-donating (ÀI, +M) groups (12f,p, 13d, 14c, 15h) with electron-withdrawing groups (ÀI: 12i, 13e, 14d, 15d, 16b; ÀM: 12u) and groups with approximately neutral electrondemand (12c,m, 13b,h,j, 14b,f,g, 15b,e,f).
Thiophene and pyridine were also investigated as aromatic heterocyclic replacements for the 3-(substituted)phenyl ring. The thiophene in 13r, 15i maintains the activity, relative to the 3-phenyl parents 12a, 15a, respectively, as expected for this conservative replacement. However, the isosteric replacement with pyridine in 13p, 14h, 15g produced some striking effects. Potency against TNKS-2 was dramatically reduced in 14h, 15g, whereas it was diminished slightly in 12p. However, 12p also inhibited the activity of PARP-1 strongly (IC 50 = 111 nM), in contrast to most of the 3-(substituted)phenyl analogues counter-screened against this isoform and found to have low potency (IC 50 = 860 nM to >10,000 nM).
The 3-aryl substituent was extended to test the boundaries and flexibility of the hydrophobic cavity and to explore the tunnel at the distal end. Firstly, a short flexible linker (-CH 2 CH 2 -) was interposed between the isoquinoline and the phenyl ring, taking the phenyl out of conjugation and pushing it towards the distal end of the cavity; this caused a marked loss of activity in 12s. Secondly, diminution in activity was also caused by replacing simple planar aryl groups at the 3-position with the 3D bulk of ferrocene in 13s. As with the mono-ortho-substituted phenyl compounds 12d,g,k, 13f, 13s can exist as a pair of interconverting enantiomeric atropisomers and it is again likely that only one atropisomer can bind.
Structure-activity relationships-entering the tunnel
The tunnel at the distal end of the cavity was probed with the rigid hydrophobic 4 0 -phenylethynyl extension in 13k. Modelling suggested that this group should occupy the whole tunnel, with the distal phenyl starting to project into solvent. This compound was potent against TNKS-2, showing that the tunnel is directly aligned with the 4 0 -position on the proximal benzene ring and can accept a long narrow hydrophobic group.
The tunnel was also exploited in designing more water-soluble analogues. The isoquinolin-1-one pharmacophore usually gives high-melting solids of low aqueous solubility. A previous attempt to introduce a water-solubilising basic aliphatic amine to the 2-phenylquinazolin-4-one core with a 4 0 -H 3 N + CH 2 but abolished inhibitory activity against the TNKSs. 36 Modelling suggested that this primary ammonium would have to be accommodated in the hydrophobic part of the tunnel, giving unfavorable interactions. Thus, in the isoquinolinone series, tertiary aliphatic amines were incorporated at the corresponding 4 0 -position on the 3-phenyl ring, to provide a solubilising salt but without compromising lipophilicity severely.
0 -(piperidin-1-yl)methyl-(13m) and 4 0 -(4-methylpiperazinyl) methyl-(13o) groups were accepted without major loss of activity but, curiously, the 4 0 -(pyrrolidin-1-yl)methyl analogue 13n had very poor potency (IC 50 = 1.2 lM). The HCl salts of 13l-o were soluble to >2.5 mg mL À1 in water. Table 2 also shows the activities of selected compounds against TNKS-1 and the results of counter-screening against PARP-1 and PARP-2. In general, the IC 50 values against TNKS-1 parallel those found for TNKS-2. Most compounds were apparently more active against TNKS-2 than they were against the TNKS-1 isoform, an effect also seen in the preliminary studies with 2-aryl-8-methylquinazolin-4-ones, 36 but the assays use different constructs of the enzyme and different formats, so detailed comparisons must be made with caution. Worthy of note, however, is the apparent extreme selectivity of 13k for inhibiting TNKS-2 (IC 50 = 10 nM), whereas no inhibition of the activity of TNKS-1 is seen up to -fold can be achieved (e.g., 14b). Selected compounds were also counter-screened against another PARP isoform, PARP-2. The 5-amino-3-arylisoquinolin-1-ones 12a,f,i,m inhibited PARP-2 moderately with IC 50 values parallelling those for inhibition of PARP-1. By contrast, the 5-methyl-, 5-fluoro-and 5-methoxy-3-arylisoquinolin-1-ones 13b,k 14b,15b did not inhibit PARP-2 activity up to 10 mM. The major exception to this poor inhibition of PARP-1 and PARP-2 is the 3-(pyridin-4-yl) compound 13p, which is essentially non-selective between the four isoforms examined and may constitute a new structural lead for inhibition of PARP-1/2.
Crystallographic studies on mode of binding
Protein crystallography was used during the studies to understand the modes of binding of the compounds to TNKSs. The catalytic domain of TNKS-2 was used in the structural studies and the structures were solved at 1.6-2.2 Å resolution. The asymmetric unit of the crystals contained two protein chains, which are almost identical at the compound-binding site. We will, therefore, only discuss chain A of the crystal structures. Importantly, the catalytic domains of TNKS-1 and TNKS-2 are highly homologous and the residues surrounding the binding sites are completely conserved. 67 The apo crystal structures of the proteins have differences in the conformations of the D-loops lining the substrate-binding site, which could indicate differences in dynamics of the proteins but may naturally also be caused by the crystal packing. 33 The current structural information does not explain the observed selectivity of 13k between the isoforms of TNKS. In total, twelve crystal structures were solved, including those of the small initial hit molecules 11a-d (PDB codes 4UVL, 4UVP, 4UVS, 4UVT, respectively) in TNKS-2, establishing the initial mode of binding of the core scaffold, as described above. The improved analogue structures 12a,f,m, 13h,n, 14f, 15e and 17 (PDB codes 4UVZ, 4UVO, 4UVN, 4UVV, 4UVU, 4UVX, 4UVY, 4UVW, respectively) with varied 3-and 5-substituents were used to rationalise the SARs.
The compounds bind to the nicotinamide-binding site in the fashion expected for a typical inhibitor of PARPs. They make the canonical H-bonds with Gly 1032 and Ser 1068 of TNKS-2 (Fig. 7a) , as well as p-stacking with Tyr
1071
. Superposition of the protein structures reveals that the ligands occupy the same cavity in all the cases and the isoquinolinone moiety is nearly identically positioned in each case. Small structural changes in the surrounding residues induced by the binding of the analogues can be detected, when the crystal structures are compared. No structural changes were observed when the structures were compared with the TNKS-2 structure with nicotinamide bound (PDB code 3U9H). 49 The initial small inhibitors 11a-d bind very similarly, with no structural changes in the protein. Binding of the aryl group in the larger derivatives 12-15, 17 causes Pro 1034 and Phe 1035 to move towards the hydrophobic extensions of the compounds (Fig. 7b) . This induced fit is driven by the enhanced hydrophobic interaction of the closer fit of the compound. This change was not observed when a bulkier compound, 13n, was bound to the active site. The long pyrrolidinyl extension towards the solvent is not well ordered in the crystal structure and the compound also has a lowered potency (Fig. 7a , Table 2 ). This contrasts with the retained activity of 13m and 13o. The dimethylaminomethyl group in 13l does not extend to the solvent region with a hydrophobic group, as is the case with 13n, and 13l retains activity. Based on the differences in potency, the best 5-substituents are electron-donating or electron-neutral. In addition, compounds with hydrophobic 4 0 -substituents may interact weakly with the Tyr 1050 (Fig. 7b) . No large structural changes in the protein were observed when comparing the co-crystal structures of 12m, 13h, 14f and 15e, which all have a 4-chlorophenyl group at the 3-position of the isoquinolinones but which vary in the 5-substituent. Only 10°rotation of the Tyr 1050 side chain was observed with the 5-methoxy derivative 15e (Fig. 7c) . This methoxy group is in close contact (ca. 3 Å) to Tyr 1071 hydroxy and to a water molecule on the protein surface (Fig. 7b) . This would indicate that the methoxy group would not be the best substitution but apparently other effects overcome these unfavorable interactions. The 5-NH 2 in 12m does not make any H-bonds with the water molecules near the binding site. The phenyl group of 17 is rotated as described above but changes in the protein residues can also be observed when this compound is bound. Tyr 1071 rotates by 26°on complexation with 17 and Tyr 1050 (including the main chain atoms) moves $0.5 Å to accommodate the 4-methyl group of the compound (Fig. 7c ).
Antiproliferative activity
In very preliminary experiments, selected examples were evaluated for their antiproliferative activity against FEK4 human fibroblasts 64 and HT29 human colon adenocarcinoma cells. 65 The effects of some 5-aminoisoquinolinones on the growth of MDA-MB-231 human breast cancer cells and on LNCaP human prostate cancer cells were also assessed. The FEK4 cell line is a model for normal non-malignant cells. HT29 cells have no BRCA mutation but do have a class-II mutation in APC. It is evident ( Table 3) Comparative studies were limited by insolubility. Compounds 12c, 13b,e,g,h,i,k, 14b, 13b were selected by the National Cancer Institute for evaluation in their 60-cell line screen (Supporting information). Most showed no or very modest inhibition of proliferation of human tumour cells at 10 lM. However, the 3-(4-methylphenyl) analogues 12c and 13b had interesting activity against MDA-MB-435 melanoma cells and were selected for evaluation in the five-concentration screen. Compounds 13e, 14b, 15b were inhibitory towards UO-31 renal cells, whereas 13g,h, 14b were active against MCF7 breast tumour cells. The five-concentration study showed that 12c had GI 50 = 250 nM for MDA-MB-435 cells and 13b had GI 50 = 316 nM for these melanoma cells and GI 50 = 341 nM for UO-31 renal carcinoma cells.
Conclusions
In this paper, we report the design, synthesis and evaluation in vitro of 3-arylisoquinolin-1-ones as inhibitors of the TNKSs, using these compounds as probes of the binding site. Compounds were designed from three structural starting-points: the crystal structures of our simple PARP-1 inhibitors 11a 40 , 11b, 51 11c 51 and 11d 52 bound into the NAD + -binding site of human TNKS-2; the crystal structure of known inhibitor 1 bound to TNKS-2; 53 'scaffold-hopping' from our 2-arylquinazolin-4-one inhibitors of the TNKSs. 36 3-Arylisoquinolin-1-ones were designed, carrying a variety of substituents at the 5-position. The position and nature of substituents on the 3-aryl group was also explored in this library, to help to define SAR and to explore the shape and boundaries of the hydrophobic cavity adjacent to the nicotinamide-binding Gly and 3-aryl-5-MeO-isoquinolin-1-ones 15 were assembled in one step by deprotonation of 3-substituted N,N,2-trimethylbenzamides with LDA and quench with benzonitriles; again diversity of the 3-aryl is introduced at a very late stage. The nature of the 5-substituent in inhibition of TNKS-2 was relatively unimportant, with 5-Me and 5-OMe analogues being slightly more active than their 5-F, 5-OH or 5-NH 2 counterparts. By contrast, a (substituted)phenyl or heteroaryl group in the 3-position was essential for activity. Substitution on this 3-phenyl was also important, with groups in the para-position generally enhancing binding and bulky substitution in one or both ortho-positions abrogating activity. The electronic and polar nature of the parasubstituent was less important; long rigid linear groups were also accepted. Also tolerated in this para-position were extensions carrying water-solubilising tertiary aliphatic amine salts. In general, potency against TNKS-1 paralleled potency against TNKS-2, with very few exceptions; this is unremarkable, since the NAD + -binding catalytic domains have a high degree of sequence identity. Most of the 3-arylisoquinolin-1-ones inhibited the TNKSs highly selectively, with much lower potency against a related enzyme, PARP-1. Many of the most potent inhibitors of the TNKSs showed >500-fold selectivity for TNKS-2 versus PARP-1, with the most selective, 14b, 15b, being >2000-fold selective. Interestingly, the SAR for inhibition of PARP-1 and of PARP-2 by these 3-arylisoquinolin-1-ones did not parallel the SAR for inhibition of TNKSs, indicating that incorporating selectivity by design was feasible. Interestingly, the 3-(pyridin-4-yl) analogue 13p proved to be a moderately good inhibitor of PARP-1, (IC 50 = 111 nM) and of PARP-2 (IC 50 = 167 nM).
The SAR was rationalised by structural studies consequent to determining the crystal structures of several analogues bound into the TNKS-2 protein. Together, the SAR and the structural studies allowed good definition of the capacity of the hydrophobic cavity to accept substituted aryl groups. The para-extensions projected into a narrow tunnel towards the exterior, indicating that this is a direction in which to seek further binding contacts for secondgeneration isoquinolin-1-one inhibitors.
Some of the compounds showed antiproliferative activity, although the link with inhibition of the tankyrases was not clear. In particular, 12c and 13b showed good inhibition of the growth of several tumour cell lines in the NCI 60-cell-line panel.
Thus the 3-arylisoquinolin-1-ones are shown to represent a class of highly potent and selective inhibitors of the TNKSs, with IC 50 of some examples (13a-d) in the 1-2 nM range. Adding water-solubilising substituents is only marginally deleterious to activity. This core is therefore identified as the foundation on which to build more complex inhibitors with optimised pharmaceutical and pharmacological properties.
Experimental
Protein crystallography
Protein crystallography experiments were carried out using human TNKS-2. The catalytic domain was expressed, purified and crystallised as previously reported. 49 Inhibitors were soaked for Data were collected at the Diamond Light Source on beamlines I038 and I04-1 and at ESRF on beamlines ID14-1, ID23-1 and ID23-2. Diffraction data were processed and scaled with the XDS package. 68 The structures were solved using the Difference Fourier method, with the starting phases derived from the TNKS2 structure (PDB accession code 3U9H) or with molecular replacement with MOLREP 69 using the TNKS2 structure (PDB accession code 3KR7) as a starting model. REFMAC5 70 was used for refinement and COOT 71 for manual building of the model. Statistics for collection of data and for refinement are shown in the Supporting information.
Biochemical and antiproliferative evaluation
Assays of inhibition of TNKS-1, TNKS-2 and PARP-1 were performed using methods described previously. 36 Assays of inhibition of PARP-2 were performed for 11a, 12a,f,i,m using a method described previously. 63 Assays of inhibition of PARP-2 were performed for 13b,k,p, 14b, 15b with human PARP-2 using a commercial kit (AMS Biosciences PARP2 Chemiluminescent Assay Kit, Catalogue # 80552, AMS Biosciences, Abingdon, Oxfordshire OX14 4SE, UK), following the protocol provided. Antiproliferative assays were conducted as described previously. 63 IC 50 values were estimated using Sigmaplot. 1H, s, 3-H 
